HF
NTLA icon

HRT Financial’s Intellia Therapeutics NTLA Stock Holding History

HRT Financial’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$292K Buy
+22,800
New +$290K ﹤0.01% 2898

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HRT Financial's NTLA Position: Q1 2026 in Review

HRT Financial reduced its Intellia Therapeutics (NTLA) stake by 34% in Q1 2026, selling an estimated $3.34M and leaving 502,337 shares worth $6.44M. The position accounts for 0.02% of the portfolio, ranked #848.

HRT Financial first reported a position in NTLA in Q3 2021 and has held it in 6 quarters since. The position peaked at $6.88M in Q4 2025. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • HRT Financial held 502,337 shares of Intellia Therapeutics worth $6.44M as of Q1 2026.
  • HRT Financial sold 262,553 Intellia Therapeutics shares in Q1 2026, an estimated $3.34M.
  • Intellia Therapeutics made up 0.02% of HRT Financial's portfolio in Q1 2026, its #848 holding.
  • HRT Financial first reported a position in Intellia Therapeutics in Q3 2021 and has held it in 6 quarters since.
  • HRT Financial's Intellia Therapeutics position peaked at $6.88M in Q4 2025.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.